Living Pharmaceutical Lives
Download Living Pharmaceutical Lives full books in PDF, epub, and Kindle. Read online free Living Pharmaceutical Lives ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author | : Peri Ballantyne |
Publisher | : Routledge |
Total Pages | : 216 |
Release | : 2021-05-12 |
Genre | : Medical |
ISBN | : 1000384004 |
Increasingly, pharmaceuticals are available as the solutions to a wide range of human health problems and health risks, minor and major. This book portrays how pharmaceutical use is, at once, a solution to, and a difficulty for, everyday life. Exploring lived experiences of people at different stages of the life course and from different countries around the world, this collection highlights the benefits as well as the challenges of using medicines on an everyday basis. It raises questions about the expectations associated with the use of medications, the uncertainty about a condition or about the duration of a medicine regimen for it, the need to negotiate the stigma associated with a condition or a type of medicine, the need to access and pay for medicines and the need to schedule medicine use appropriately, and the need to manage medicines’ effects and side effects. The chapters include original empirical research, literature review and theoretical analysis, and convey the sociological and phenomenological complexity of ‘living pharmaceutical lives’. This book is of interest to all those studying and researching social pharmacy and the sociology of health and illness.
Author | : Joseph Dumit |
Publisher | : Duke University Press |
Total Pages | : 277 |
Release | : 2012-09-03 |
Genre | : Business & Economics |
ISBN | : 0822348713 |
Challenges our understanding of health, risks, facts, and clinical trials [Payot]
Author | : Laurence Monnais |
Publisher | : Cambridge University Press |
Total Pages | : 291 |
Release | : 2019-08-22 |
Genre | : History |
ISBN | : 1108474667 |
Innovative examination of the early globalization of the pharmaceutical industry, arguing that colonialism was crucial to the worldwide diffusion of modern medicines.
Author | : National Academies of Sciences, Engineering, and Medicine |
Publisher | : National Academies Press |
Total Pages | : 235 |
Release | : 2018-03-01 |
Genre | : Medical |
ISBN | : 0309468086 |
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author | : Rebecca Skloot |
Publisher | : Crown |
Total Pages | : 386 |
Release | : 2010-02-02 |
Genre | : Science |
ISBN | : 0307589382 |
#1 NEW YORK TIMES BESTSELLER • “The story of modern medicine and bioethics—and, indeed, race relations—is refracted beautifully, and movingly.”—Entertainment Weekly NOW A MAJOR MOTION PICTURE FROM HBO® STARRING OPRAH WINFREY AND ROSE BYRNE • ONE OF THE “MOST INFLUENTIAL” (CNN), “DEFINING” (LITHUB), AND “BEST” (THE PHILADELPHIA INQUIRER) BOOKS OF THE DECADE • ONE OF ESSENCE’S 50 MOST IMPACTFUL BLACK BOOKS OF THE PAST 50 YEARS • WINNER OF THE CHICAGO TRIBUNE HEARTLAND PRIZE FOR NONFICTION NAMED ONE OF THE BEST BOOKS OF THE YEAR BY The New York Times Book Review • Entertainment Weekly • O: The Oprah Magazine • NPR • Financial Times • New York • Independent (U.K.) • Times (U.K.) • Publishers Weekly • Library Journal • Kirkus Reviews • Booklist • Globe and Mail Her name was Henrietta Lacks, but scientists know her as HeLa. She was a poor Southern tobacco farmer who worked the same land as her slave ancestors, yet her cells—taken without her knowledge—became one of the most important tools in medicine: The first “immortal” human cells grown in culture, which are still alive today, though she has been dead for more than sixty years. HeLa cells were vital for developing the polio vaccine; uncovered secrets of cancer, viruses, and the atom bomb’s effects; helped lead to important advances like in vitro fertilization, cloning, and gene mapping; and have been bought and sold by the billions. Yet Henrietta Lacks remains virtually unknown, buried in an unmarked grave. Henrietta’s family did not learn of her “immortality” until more than twenty years after her death, when scientists investigating HeLa began using her husband and children in research without informed consent. And though the cells had launched a multimillion-dollar industry that sells human biological materials, her family never saw any of the profits. As Rebecca Skloot so brilliantly shows, the story of the Lacks family—past and present—is inextricably connected to the dark history of experimentation on African Americans, the birth of bioethics, and the legal battles over whether we control the stuff we are made of. Over the decade it took to uncover this story, Rebecca became enmeshed in the lives of the Lacks family—especially Henrietta’s daughter Deborah. Deborah was consumed with questions: Had scientists cloned her mother? Had they killed her to harvest her cells? And if her mother was so important to medicine, why couldn’t her children afford health insurance? Intimate in feeling, astonishing in scope, and impossible to put down, The Immortal Life of Henrietta Lacks captures the beauty and drama of scientific discovery, as well as its human consequences.
Author | : Jörg Blech |
Publisher | : Taylor & Francis |
Total Pages | : 148 |
Release | : 2023-05-09 |
Genre | : Medical |
ISBN | : 1000938573 |
This is a highly accessible and reassuring account of how the pharmaceutical industry is redefining health, making it a state that is almost impossible to achieve. Many normal life processes – states as natural as birth, ageing, sexuality, unhappiness and death – are systematically being reinterpreted as pathological so creating new markets for their treatments. In this enlightening book, Jörg Blech reveals: how the invention of diseases by pharmaceutical companies is turning us all into patients, and how we can protect ourselves against this how the medical profession has been bullied and co-opted into endorsing profitable cures for people who aren't ill fears about how pharmaceutical companies create markets by playing on the general public's concern with their health A self-help book in the truest sense, Inventing Disease and Pushing Pills reassures us about our own health. It is essential reading for doctors, nurses and patients alike.
Author | : Lee Harland |
Publisher | : Elsevier |
Total Pages | : 583 |
Release | : 2012-10-31 |
Genre | : Computers |
ISBN | : 1908818247 |
The free/open source approach has grown from a minor activity to become a significant producer of robust, task-orientated software for a wide variety of situations and applications. To life science informatics groups, these systems present an appealing proposition - high quality software at a very attractive price. Open source software in life science research considers how industry and applied research groups have embraced these resources, discussing practical implementations that address real-world business problems.The book is divided into four parts. Part one looks at laboratory data management and chemical informatics, covering software such as Bioclipse, OpenTox, ImageJ and KNIME. In part two, the focus turns to genomics and bioinformatics tools, with chapters examining GenomicsTools and EBI Atlas software, as well as the practicalities of setting up an 'omics' platform and managing large volumes of data. Chapters in part three examine information and knowledge management, covering a range of topics including software for web-based collaboration, open source search and visualisation technologies for scientific business applications, and specific software such as DesignTracker and Utopia Documents. Part four looks at semantic technologies such as Semantic MediaWiki, TripleMap and Chem2Bio2RDF, before part five examines clinical analytics, and validation and regulatory compliance of free/open source software. Finally, the book concludes by looking at future perspectives and the economics and free/open source software in industry. - Discusses a broad range of applications from a variety of sectors - Provides a unique perspective on work normally performed behind closed doors - Highlights the criteria used to compare and assess different approaches to solving problems
Author | : Martin A. Voet |
Publisher | : BrownWalker Press |
Total Pages | : 240 |
Release | : 2020-05-01 |
Genre | : Law |
ISBN | : 1627347461 |
This Sixth Edition of The Generic Challenge provides important new updates on current regulatory, legal and commercial issues affecting brand and generic pharmaceutical products, including new laws establishing generics for biologics, and changes brought about by the recently enacted America Invents Act. It explains clearly and understandably the roles of patents, FDA regulation of drugs and the Hatch Waxman Act in commercial drug development in light of generic challenges and how improvements in innovative drug products provide benefits to patients while extending the commercial lives of the drugs. There is simply no other book of its kind on this important subject.
Author | : Brian D. Smith |
Publisher | : Routledge |
Total Pages | : 100 |
Release | : 2019-06-26 |
Genre | : Medical |
ISBN | : 0429663773 |
The healthcare professionals who save and extend our lives are helpless without the medicines and technologies that have revolutionised medical care. But the industry that invents, makes and provides these indispensable tools is transforming under the pressure of ageing populations, globalisation and revolutions in biological and information technology. How this industry adapts and evolves is vitally important to every one of us. This book looks inside the heads and hearts of the people who lead the global pharmaceutical and medical technology industry. It describes how they make sense of their markets and the wider life sciences economy. It reveals what they have learned about how to lead large, complex organisations to compete in dynamic, global markets. Leadership in the Life Sciences is essential reading for anyone working in or with the pharmaceutical and medical technology industry and its halo of supporting companies. Written as ten succinct lessons, it gives the reader unique insight into what the industry’s leaders are thinking. Covering topics from leadership to organisational culture, from change management to digital disruption and from competitive strategy to value-creation, each chapter distils the accumulated wisdom of those who lead the complex and turbulent life sciences industry.
Author | : Melinda E. Cooper |
Publisher | : University of Washington Press |
Total Pages | : 233 |
Release | : 2011-02-01 |
Genre | : Science |
ISBN | : 0295990317 |
Focusing on the period between the 1970s and the present, Life as Surplus is a pointed and important study of the relationship between politics, economics, science, and cultural values in the United States today. Melinda Cooper demonstrates that the history of biotechnology cannot be understood without taking into account the simultaneous rise of neoliberalism as a political force and an economic policy. From the development of recombinant DNA technology in the 1970s to the second Bush administration's policies on stem cell research, Cooper connects the utopian polemic of free-market capitalism with growing internal contradictions of the commercialized life sciences. The biotech revolution relocated economic production at the genetic, microbial, and cellular level. Taking as her point of departure the assumption that life has been drawn into the circuits of value creation, Cooper underscores the relations between scientific, economic, political, and social practices. In penetrating analyses of Reagan-era science policy, the militarization of the life sciences, HIV politics, pharmaceutical imperialism, tissue engineering, stem cell science, and the pro-life movement, the author examines the speculative impulses that have animated the growth of the bioeconomy. At the very core of the new post-industrial economy is the transformation of biological life into surplus value. Life as Surplus offers a clear assessment of both the transformative, therapeutic dimensions of the contemporary life sciences and the violence, obligation, and debt servitude crystallizing around the emerging bioeconomy.